Probiotics for Babies: Strains and Benefits

What Are Probiotics?

Probiotics are live microorganisms — primarily bacteria and some yeasts — that, when consumed in sufficient quantities, confer a health benefit on the host. The concept dates back to the early 20th century, when Nobel laureate Élie Metchnikoff observed that Bulgarian peasants who consumed fermented milk lived longer. Today, probiotics are among the most widely studied dietary supplements for both adults and children.

The human gastrointestinal tract holds trillions of microorganisms collectively known as the gut microbiota. In babies, this ecosystem begins developing at birth. It is shaped by delivery method (vaginal vs. cesarean), feeding type (breast milk vs. formula), antibiotic exposure, and environment. A healthy gut microbiota plays a crucial role in digestion, immune development, nutrient synthesis, and even neurological function through the gut-brain axis.

According to the FAO/WHO expert consultation (Food and Agriculture Organization), working with the World Health Organization, probiotics are defined as “live microorganisms which when administered in adequate amounts confer a health benefit on the host.” The definition makes two points: the organisms must be alive when consumed, and the dose must be large enough to produce a measurable effect.

For babies, the gut microbiota is particularly immature and vulnerable to disruption. During the first three years of life, the microbial community undergoes rapid colonization and diversification. Probiotics can support this process by promoting beneficial bacteria, inhibiting pathogens, strengthening the intestinal barrier, and modulating immune responses. The National Center for Complementary and Integrative Health (NCCIH) at the NIH notes that probiotics may help establish a healthier microbial balance during this critical window.

One thing matters above all: not all probiotics are the same. Different species and strains have distinct properties, mechanisms, and clinical evidence. A benefit demonstrated for one strain cannot be assumed for another, even within the same species. This is why strain-specific research matters.

How Probiotics Work in a Baby’s Gut

Understanding how probiotics function helps parents see why strain selection and dosage matter. When a baby consumes a probiotic, or receives beneficial bacteria through breast milk, the microorganisms interact with the gut ecosystem in several ways:

• Competitive exclusion. Beneficial bacteria compete with harmful pathogens for nutrients and adhesion sites on the intestinal lining. By occupying these niches, probiotics keep disease-causing organisms from establishing themselves.
• Production of antimicrobial substances. Many probiotic strains produce organic acids (lactic and acetic acid), hydrogen peroxide, and bacteriocins. Together they lower gut pH and make the environment inhospitable for pathogens.
• Enhancement of the intestinal barrier. Probiotics support the intestinal lining by promoting tight junction proteins and mucus. This reduces intestinal permeability — sometimes called “leaky gut” — and blocks toxins and allergens from slipping into the bloodstream.
• Immune system modulation. The gut-associated lymphoid tissue (GALT) holds roughly 70% of the body’s immune cells. Probiotics interact with those cells, promoting a balanced response: more immunoglobulin A (IgA), better-regulated T-helper cells, and anti-inflammatory cytokine production.
• Nutrient synthesis and metabolism. Certain strains help synthesize vitamins (particularly B vitamins and vitamin K) and aid digestion and absorption, including of lactose.

For newborns and young infants, whose immune and digestive systems are still maturing, these mechanisms are especially valuable. Breast milk naturally carries both probiotics (transferred from the mother’s gut and skin) and prebiotics — specifically human milk oligosaccharides (HMOs) — that selectively feed beneficial bacteria, particularly Bifidobacterium species.

Key Probiotic Strains for Babies: What the Evidence Shows

Not all probiotics are appropriate for infants, and not all products have been rigorously studied in children. These strains have the strongest evidence base, supported by systematic reviews, randomized trials, and pediatric guidelines.

Lactobacillus rhamnosus GG (LGG)

Lactobacillus rhamnosus GG, often abbreviated LGG, is one of the most studied probiotic strains in the world. Isolated originally from a healthy human intestinal tract, LGG has drawn over 1,000 scientific publications and more than 300 clinical trials.

For babies, the strongest evidence supports LGG for preventing and managing antibiotic-associated diarrhea (AAD). A landmark Cochrane systematic review published in 2019 analyzed 33 randomized trials involving over 6,000 children. It found that probiotic use, particularly LGG, cut the incidence of AAD from 19% to 8%. That is a clinically meaningful drop — one that can help babies finish their antibiotics without the extra burden of diarrhea.

LGG has also been studied for infant colic. A 2014 randomized trial in JAMA Pediatrics found that breastfed colicky infants given LGG had a significant drop in daily crying time versus placebo after 21 days. Later studies were more mixed, and a 2019 systematic review in Pediatrics concluded the evidence for LGG in colic is more modest than first thought — with stronger effects in breastfed than formula-fed infants.

LGG also shows promise in preventing eczema and atopic dermatitis in high-risk infants. A Finnish study in The Lancet (2001) found that prenatal plus postnatal LGG reduced eczema incidence at age 2 in children with a family history of atopic disease. Later meta-analyses confirmed a modest but statistically significant protective effect, especially when supplementation starts prenatally and runs through the first six months.

The American Academy of Pediatrics acknowledges that LGG carries the most robust evidence among probiotic strains for pediatric use, particularly for preventing antibiotic-associated diarrhea.

Bifidobacterium infantis

Bifidobacterium infantis is one of the dominant species in the gut of healthy, breastfed infants. Breastfed babies typically carry a microbiota that is 60–90% Bifidobacterium. Formula-fed infants show a more diverse but less Bifidobacterium-dominant profile.

B. infantis suits the infant gut especially well because it metabolizes human milk oligosaccharides (HMOs) — complex sugars babies cannot digest alone. By consuming HMOs, B. infantis produces short-chain fatty acids (SCFAs) that nourish intestinal cells, lower gut pH, and inhibit pathogens. That makes it a keystone species in the breastfed infant gut.

The evidence for B. infantis in colic management is particularly compelling. A 2007 study in Pediatrics by Savino and colleagues showed that Bifidobacterium supplementation reduced colic symptoms in breastfed infants. More recently, a 2019 randomized trial in Alimentary Pharmacology & Therapeutics found that a specific strain (B. infantis EVC001) significantly raised infant fecal Bifidobacterium levels and lowered intestinal inflammation markers in colicky infants. Those receiving the probiotic cried less, had better stool consistency, and showed lower levels of pro-inflammatory cytokines.

Beyond colic, B. infantis may support immune development and reduce allergic risk. Research in Pediatric Research links an early Bifidobacterium-dominant microbiota with appropriate immune maturation and lower rates of food allergy and asthma later in childhood.

Product caveat: not all Bifidobacterium infantis products are equivalent. The strain designation matters enormously. EVC001 carries the strongest evidence, yet many commercial products do not name their strain — or use strains with little or no infant clinical data.

Saccharomyces boulardii

Saccharomyces boulardii is a beneficial yeast, not a bacterial probiotic. That distinction matters clinically: as a yeast, it is naturally resistant to antibiotics. It can be given alongside antibiotic treatment without being destroyed — which makes it particularly useful for preventing antibiotic-associated diarrhea in babies.

The evidence for preventing AAD is robust. A 2015 meta-analysis in the European Journal of Pediatrics reviewed nine randomized trials involving over 1,500 children and concluded that S. boulardii significantly reduced AAD risk in pediatric populations. The protective effect held across different antibiotic classes and age groups, infants included.

S. boulardii has also been studied in acute infectious diarrhea. A Cochrane systematic review found it reduced the duration of acute gastroenteritis in children by about one day. For parents managing a stomach bug, one day means less dehydration risk, fewer sleepless nights, and a quicker return to normal feeding.

It has additionally shown benefit in reducing the severity of necrotizing enterocolitis (NEC) in preterm infants. A 2020 meta-analysis in JAMA Pediatrics found that prophylactic probiotic supplementation — often including S. boulardii — reduced NEC incidence in premature babies. To be clear: this use is strictly a medical decision made in neonatal intensive care, not something parents should attempt at home.

The NCCIH recognizes S. boulardii as one of the better-studied probiotic organisms, with evidence supporting its use in preventing antibiotic-associated diarrhea.

Other Notable Strains

Three strains above lead the evidence, but others show promise in children:

• Lactobacillus reuteri DSM 17938. Studied specifically for colic. A 2010 study by Szajewska and colleagues in The Journal of Pediatrics found it cut crying time in breastfed colicky infants by about 50% after three weeks. Evidence is less consistent in formula-fed infants, and a 2019 Cochrane review called for larger, more rigorous trials.
• Bifidobacterium lactis BB-12. Widely used in infant formulas; shown to support digestive health and possibly reduce respiratory infections. Generally considered safe and well tolerated.
• Lactobacillus acidophilus. Common in yogurt and fermented foods. Generally safe, but the infant evidence is less robust than for LGG or B. infantis.

Benefits of Probiotics for Babies: A Closer Look

Colic Management

Infant colic — crying more than three hours a day, more than three days a week, for more than three weeks — affects up to 20% of infants in the first months. It is generally benign and self-resolving by 3–4 months, yet it remains one of the most distressing challenges new parents face.

The gut-microbiota connection has drawn serious research attention. Colicky infants often show lower levels of Lactobacillus and Bifidobacterium and higher levels of proteobacteria (many potentially pathogenic) than non-colicky infants. This dysbiosis may drive gut inflammation, gas, and intestinal discomfort that shows up as excessive crying.

Probiotics aim to correct that imbalance. The evidence so far:

• Lactobacillus rhamnosus GG may modestly reduce crying time, especially in breastfed infants.
• Bifidobacterium infantis EVC001 has reduced crying time and improved stool consistency in colicky breastfed infants.
• Lactobacillus reuteri DSM 17938 has worked in several studies; one meta-analysis suggests it is the most effective single strain for colic in breastfed babies.

The AAP emphasizes that while probiotics show promise for colic, they are no guaranteed solution. Discuss probiotic use with your pediatrician — colic can sometimes signal an underlying condition that needs different treatment.

Preventing and Managing Diarrhea

Diarrhea is a leading cause of illness in children worldwide, and even in developed countries it remains a common reason for pediatric visits and hospitalizations. Probiotics can play a role in both prevention and treatment.

Antibiotic-associated diarrhea is one of the most common side effects of antibiotic therapy in children, occurring in 5–30% of cases depending on the antibiotic. By disrupting normal gut flora, antibiotics create room for pathogens like Clostridioides difficile to multiply. Probiotics — particularly LGG and S. boulardii — can help hold microbial balance during treatment.

Acute infectious gastroenteritis from rotavirus, norovirus, or bacterial pathogens is another area where probiotics may help. ESPGHAN (the European Society for Pediatric Gastroenterology, Hepatology and Nutrition) has issued guidelines recommending Lactobacillus rhamnosus GG and Saccharomyces boulardii as adjuncts to rehydration therapy in children with acute gastroenteritis. Evidence suggests these strains can shorten diarrhea by about one day and reduce stool frequency.

The World Health Organization emphasizes that oral rehydration therapy remains the cornerstone of diarrhea management. Probiotics are supportive therapy that complements standard care — never a replacement for it.

Eczema and Allergic Conditions

Atopic dermatitis (eczema) is the most common inflammatory skin condition in children, affecting up to 20% of infants in developed countries. The link between gut microbiota and allergic disease drives major research, with the “hygiene hypothesis” proposing that reduced microbial exposure in early life contributes to rising allergy rates.

Studies on whether probiotics during pregnancy and infancy reduce eczema risk give mixed but generally encouraging results:

• A 2018 meta-analysis in Pediatric Allergy and Immunology found that supplementation during the last trimester of pregnancy and early infancy cut eczema risk by about 20% in high-risk infants.
• LGG carries the strongest evidence for eczema prevention, particularly when mothers with a history of atopy start it prenatally and continue postnatally.
• Effects are strain-specific and timing-dependent. Probiotics started only after birth may work less well than prenatal starts.

Still, the AAP and other major pediatric organizations do not currently recommend routine probiotic supplementation solely for allergy prevention. The evidence is promising but not yet consistent enough for a universal recommendation. More research is needed on which strains, doses, and timing work best.

Supporting Preterm Infant Health

Premature babies — especially those born before 32 weeks — face much higher risks of gut-related disease. Necrotizing enterocolitis (NEC) and late-onset sepsis are two devastating complications of prematurity linked to gut dysbiosis.

Multiple large studies and meta-analyses show probiotic supplementation in preterm infants can reduce NEC and mortality. A 2020 Cochrane review of 56 randomized trials involving over 10,000 preterm infants found probiotics reduced NEC risk by about 50% and reduced all-cause mortality.

Despite this, the AAP has issued no universal recommendation for preterm infants, citing concerns about product standardization, strain selection, and the risk of probiotic translocation in immunocompromised infants. Probiotic use in NICUs remains an institutional decision — parents of premature babies should discuss it with their neonatology team.

Safety of Probiotics in Babies

One of the most common questions parents ask: are probiotics safe for my baby? The answer depends on the infant’s health status.

For healthy, term-born babies: probiotics are generally considered safe and well tolerated. Decades of research and widespread use show a strong safety profile. The most common side effects are mild and transient — gas, bloating, and changes in stool consistency — typically resolving within the first few days as the gut adjusts.

For immunocompromised or critically ill infants: caution is warranted. Rare case reports describe probiotic bacteremia (bacteria in the bloodstream) and fungemia (yeast in the bloodstream) in premature infants, severely immunocompromised children, and those with central venous catheters. These cases are extremely rare but serious. The AAP advises against routine probiotic use in immunocompromised infants without medical supervision.

Product quality concerns: unlike drugs, probiotic supplements are regulated as dietary supplements in the United States. They do not undergo the same rigorous premarket testing for safety and efficacy. Studies have found some products contain fewer live organisms than stated, different strains than declared, or contaminants. Choose products from reputable manufacturers that undergo third-party testing.

The U.S. Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA) both stress strain identification and quality control in probiotic products. The NIH recommends looking for specific strain designations — not just genus and species — and products tested for purity and potency.

• Never give probiotics to a baby with a compromised immune system without medical supervision.
• Check with your pediatrician if your baby has a central venous catheter or a history of surgery.
• Stop use and call your doctor if your baby develops fever, unusual fussiness, or signs of infection.
• Always follow the dosage on the product label or given by your pediatrician.

How to Choose a Probiotic for Your Baby

The probiotic market is vast and often confusing. With hundreds of products, an informed choice needs a checklist.

1. Strain Specificity

The most important factor is the specific strain, not just genus and species. Lactobacillus rhamnosus GG has extensive evidence; other L. rhamnosus strains may not share its properties. Look for the full strain designation on the label.

2. Evidence-Based Strains

Choose strains with published clinical research in infants: LGG, B. infantis EVC001, S. boulardii, and L. reuteri DSM 17938 carry the strongest pediatric evidence.

3. Appropriate CFU Count

Colony-forming units (CFUs) count live organisms per dose. For infants, research generally supports 1–10 billion CFU per day, depending on strain and goal. More is not always better — excessive doses can cause digestive discomfort without extra benefit.

4. Delivery Format

• Liquid drops: most common for infants; easy to give directly or mixed with breast milk or formula.
• Powder sachets: mix with cool (not hot) food or liquid.
• Chewable tablets: for older toddlers who can chew safely.

5. Third-Party Testing

Look for independent verification by USP (United States Pharmacopeia), NSF International, or ConsumerLab. These marks confirm the product contains what it claims and is free from contaminants.

6. Storage Requirements

Some probiotics need refrigeration; others are shelf-stable. Check the label and follow storage instructions. A probiotic stored improperly may contain few or no live organisms.

7. Added Ingredients

Check for unnecessary additives, allergens, or artificial ingredients. Some infant probiotics are made without common allergens (dairy, soy, gluten) — important for babies with known sensitivities.

8. Consult Your Pediatrician

Perhaps the most important step. Your pediatrician can recommend specific strains and doses for your baby’s health needs, medical history, and any current conditions.

Dosage Guidelines for Babies

The right dose depends on the strain, the infant’s age and weight, and the health condition being addressed.

General Dosage Ranges

Based on clinical research, these ranges have been studied in infants:

• 1–5 billion CFU/day: common for general digestive support and colic management.
• 5–10 billion CFU/day: typically used for preventing antibiotic-associated diarrhea.
• 10+ billion CFU/day: used in some therapeutic contexts, but only under medical guidance.

Important Dosage Considerations

• Start low, go slow. If your baby is new to probiotics, begin at the lower end of the range and increase gradually if needed. This lets the gut adjust and minimizes temporary gas.
• Timing with antibiotics. To prevent antibiotic-associated diarrhea, give the probiotic at least 2 hours before or after the antibiotic dose. Spacing keeps the antibiotic from immediately killing the probiotic.
• Duration of use. It depends on the goal. For AAD prevention, continue through the antibiotic course plus one week after. For colic, studies typically run 3–4 weeks. For general digestive health, discuss duration with your pediatrician.
• Consistency matters. Probiotics work only while being taken. Unlike supplements that build up in the body, they need daily use to hold their effect. Stop, and the microbiota gradually returns to its previous state.

Special Populations

• Premature infants: dosing must come from the neonatology team. Products for term infants may not suit premature babies.
• Babies with medical conditions: infants with immune disorders, short bowel syndrome, or other complex conditions need individualized dosing and strain selection under medical supervision.

Probiotics vs. Prebiotics vs. Synbiotics

Parents meet these related terms and wonder about the differences:

• Probiotics are live microorganisms that confer a health benefit. Examples: L. rhamnosus GG, B. infantis, S. boulardii.
• Prebiotics are non-digestible food components that selectively feed beneficial gut bacteria. The best known are human milk oligosaccharides (HMOs) in breast milk, plus fructo-oligosaccharides (FOS) and galacto-oligosaccharides (GOS) added to some formulas.
• Synbiotics combine both. The prebiotic nourishes the probiotic organism, potentially improving its survival and colonization. Some infant formulas now include synbiotic blends.

For most parents, focusing on a well-researched probiotic supplement is enough. Prebiotics are naturally present in breast milk, and prebiotic-added formulas are widely available. Synbiotic products may offer extra benefits, but evidence comparing them with probiotics alone is still emerging.

Frequently Asked Questions About Baby Probiotics

The Bottom Line

Probiotics are a promising area of pediatric research with growing evidence for specific conditions in babies. Six points to remember:

• Strain matters. LGG, B. infantis, and S. boulardii have the strongest infant evidence.
• Evidence supports specific uses: preventing antibiotic-associated diarrhea, easing colic in breastfed infants, and possibly preventing eczema in high-risk babies.
• Safety is generally good for healthy, term infants — with caution for immunocompromised babies and those with central lines.
• Quality varies. Choose reputable manufacturers that specify strain designations and use third-party testing.
• Consult your pediatrician before starting any probiotic, especially if your baby is premature or has a medical condition.
• Probiotics are not a replacement for medical treatment. They are supportive therapy that works best alongside appropriate medical care, nutrition, and feeding practices.

The field keeps evolving: next-generation probiotics, strain combinations, personalized microbiome therapies, and the gut microbiome’s role in long-term health are all under active study. For now, parents can feel confident that used appropriately and under medical guidance, probiotics are a safe and potentially beneficial tool for supporting their baby’s gut health.

Related guides

• Baby Antibiotic Diarrhea
• Baby Gas Drops Simethicone
• More in Feeding guides.

References and further reading

• FAO/WHO — Health and Nutritional Properties of Probiotics in Food (definition of probiotics).
• NIH National Center for Complementary and Integrative Health — Probiotics: What You Need to Know.
• World Health Organization — Diarrhoeal disease fact sheet (oral rehydration as cornerstone).
• U.S. FDA — Dietary Supplements.
• American Academy of Pediatrics — probiotic use in children (cited by name).
• European Food Safety Authority (EFSA) — probiotic strain identification and quality control (cited by name).